Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
Authors
Keywords
-
Journal
ANNALS OF NEUROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-05-29
DOI
10.1002/ana.25775
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
- (2019) Alan J. Fowler et al. Drugs in research & development
- Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
- (2018) Maya Jeitany et al. EMBO Molecular Medicine
- Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly
- (2018) Ingmar Skoog et al. JOURNAL OF ALZHEIMERS DISEASE
- Tau clearance improves astrocytic function and brain glutamate-glutamine cycle
- (2018) Michaeline L. Hebron et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models
- (2017) Michaeline Hebron et al. JOURNAL OF NEUROIMMUNOLOGY
- The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment
- (2017) A H Ashok et al. MOLECULAR PSYCHIATRY
- Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis
- (2016) Lanier Heyburn et al. JOURNAL OF NEUROCHEMISTRY
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
- (2016) Clifford R. Jack et al. NEUROLOGY
- Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
- (2016) Y. Iturria-Medina et al. Nature Communications
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models
- (2015) I. Lonskaya et al. NEUROSCIENCE
- c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
- (2014) Anne-Laure Mahul-Mellier et al. HUMAN MOLECULAR GENETICS
- Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
- (2014) Irina Lonskaya et al. Molecular Neurodegeneration
- The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
- (2014) Senthilkumar S. Karuppagounder et al. Scientific Reports
- Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
- (2013) Irina Lonskaya et al. EMBO Molecular Medicine
- Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinson's disease models
- (2013) M. L. Hebron et al. HUMAN MOLECULAR GENETICS
- Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance
- (2013) Irina Lonskaya et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Parkin Ubiquitinates Tar-DNA Binding Protein-43 (TDP-43) and Promotes Its Cytosolic Accumulation via Interaction with Histone Deacetylase 6 (HDAC6)
- (2012) Michaeline L. Hebron et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons
- (2011) Tomasz Skorski CHEMISTRY & BIOLOGY
- Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated A in AD models
- (2011) P. J. Khandelwal et al. HUMAN MOLECULAR GENETICS
- Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
- (2011) Henryk Barthel et al. LANCET NEUROLOGY
- Epidemiology of Alzheimer disease
- (2011) Christiane Reitz et al. Nature Reviews Neurology
- β-Amyloid1–42Gene Transfer Model Exhibits Intraneuronal Amyloid, Gliosis, Tau Phosphorylation, and Neuronal Loss
- (2010) G. William Rebeck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia
- (2008) David L. DeRemer et al. CLINICAL THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now